{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T20:08:10Z","timestamp":1793909290963,"version":"4.8.0"},"reference-count":140,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.biopha.2018.08.138","type":"journal-article","created":{"date-parts":[[2018,9,5]],"date-time":"2018-09-05T18:50:35Z","timestamp":1536173435000},"page":"1564-1582","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":214,"special_numbering":"C","title":["A review on recent drug delivery systems for posterior segment of eye"],"prefix":"10.1016","volume":"107","author":[{"given":"Kritika","family":"Nayak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5907-4659","authenticated-orcid":false,"given":"Manju","family":"Misra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2018.08.138_bib0005","doi-asserted-by":"crossref","first-page":"49","DOI":"10.15171\/bi.2016.07","article-title":"Advanced drug delivery and targeting technologies for the ocular diseases","volume":"6","author":"Barar","year":"2016","journal-title":"BioImpacts"},{"key":"10.1016\/j.biopha.2018.08.138_bib0010","volume":"2010","author":"Pascolini","year":"2010"},{"key":"10.1016\/j.biopha.2018.08.138_bib0015","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/nrd3745","article-title":"Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma","volume":"11","author":"Zhang","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biopha.2018.08.138_bib0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/187221111794109529","article-title":"Recent advances in intraocular drug delivery systems","volume":"5","author":"Yasukawa","year":"2011","journal-title":"Recent Pat. Drug Deliv. Formul."},{"key":"10.1016\/j.biopha.2018.08.138_bib0025","first-page":"710","article-title":"Colloidal drug delivery system: amplify the ocular delivery","volume":"23","author":"Ameeduzzafar","year":"2014","journal-title":"Drug Deliv."},{"key":"10.1016\/j.biopha.2018.08.138_bib0030","series-title":"Ocul. Drug Deliv. Adv. Challenges Appl.","first-page":"131","article-title":"Progress of controlled drug delivery systems in topical ophthalmology: focus on nano and micro drug carriers","author":"Zafar","year":"2016"},{"key":"10.1016\/j.biopha.2018.08.138_bib0035","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.exer.2015.05.002","article-title":"The real reason for having a meibomian lipid layer covering the outer surface of the tear film - a review","volume":"137","author":"Millar","year":"2015","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.biopha.2018.08.138_bib0040","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1167\/iovs.02-0731","article-title":"Precorneal and pre- and postlens tear film thickness measured indirectly with optical coherence tomography","volume":"44","author":"Wang","year":"2003","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.biopha.2018.08.138_bib0045","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1021\/js9802594","article-title":"Permeability of cornea, sclera, and conjunctiva: a literature analysis for drug delivery to the eye","volume":"87","author":"Prausnitz","year":"1998","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.biopha.2018.08.138_bib0050","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3390\/polym3010193","article-title":"Recent advances in ocular drug delivery systems","volume":"3","author":"Kuno","year":"2011","journal-title":"Polymers (Basel)"},{"key":"10.1016\/j.biopha.2018.08.138_bib0055","first-page":"11","article-title":"Permeation through cornea","volume":"39","author":"Malhotra","year":"2001","journal-title":"Indian J. Exp. Biol."},{"key":"10.1016\/j.biopha.2018.08.138_bib0060","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2174\/1872211308666140130093301","article-title":"Drug delivery to the back of the eye following topical administration: an update on research and patenting activity, recent pat","volume":"8","author":"Boddu","year":"2014","journal-title":"Drug Deliv. Formul."},{"key":"10.1016\/j.biopha.2018.08.138_bib0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep21881","article-title":"Receptor-targeted liposome-peptide-siRNA nanoparticles represent an efficient delivery system for MRTF silencing in conjunctival fibrosis","volume":"6","author":"Yu-Wai-Man","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2018.08.138_bib0070","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1167\/iovs.09-5051","article-title":"An antiviral small-interfering RNA simultaneously effective against the most prevalent enteroviruses causing acute hemorrhagic conjunctivitis","volume":"52","author":"Jun","year":"2011","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.biopha.2018.08.138_bib0075","unstructured":"A.I. Jimenez, C. Paneda, T. Martinez, siRNa and their use in methods and compositions for inhibiting the expression of the ORAI1 gene, US 2016\/0304880 A1, 2016."},{"key":"10.1016\/j.biopha.2018.08.138_bib0080","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.bihy.2009.04.003","article-title":"The potential therapeutic of siRNA eye drops in ocular diseases","volume":"2","author":"Nie","year":"2009","journal-title":"Biosci. Hypotheses"},{"key":"10.1016\/j.biopha.2018.08.138_bib0085","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.ejpb.2004.12.007","article-title":"Roles of the conjunctiva in ocular drug delivery: a review of conjunctival transport mechanisms and their regulation","volume":"60","author":"Hosoya","year":"2005","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.biopha.2018.08.138_bib0090","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s13346-017-0399-y","article-title":"Ex vivo permeation of erythropoietin through porcine conjunctiva, cornea, and sclera","volume":"7","author":"Resende","year":"2017","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.biopha.2018.08.138_bib0095","article-title":"Anti-angiogenesis through noninvasive to minimally invasive intraocular delivery of the peptide CC12 identified by in vivo-directed evaluation","volume":"9","author":"Chen","year":"2016","journal-title":"Biomaterials"},{"key":"10.1016\/j.biopha.2018.08.138_bib0100","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.intimp.2017.02.024","article-title":"An inhibitor peptide of toll-like receptor 2 shows therapeutic potential for allergic conjunctivitis","volume":"46","author":"Xu","year":"2017","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.biopha.2018.08.138_bib0105","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1248\/bpb.23.1524","article-title":"Modification of ocular permeability of peptide drugs by absorption promoters","volume":"23","author":"Sasaki","year":"2000","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.biopha.2018.08.138_bib0110","series-title":"Drug Absorpt. Stud. Situ, Vitr. Silico Model.","article-title":"The conjunctival barrier in ocular drug delivery","author":"Gukasyan","year":"2008"},{"key":"10.1016\/j.biopha.2018.08.138_bib0115","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1208\/s12248-010-9183-3","article-title":"Ocular drug delivery","volume":"12","author":"Gaudana","year":"2010","journal-title":"AAPS J."},{"key":"10.1016\/j.biopha.2018.08.138_bib0120","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1089\/jop.2015.0047","article-title":"Recent advances in topical ocular drug delivery","volume":"32","author":"Yellepeddi","year":"2015","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2018.08.138_bib0125","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/978-981-10-2627-0_3","article-title":"Anatomy and physiology of the crystalline lens","author":"Chen","year":"2017","journal-title":"Pediatr. Lens Dis."},{"key":"10.1016\/j.biopha.2018.08.138_bib0130","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.visres.2009.10.013","article-title":"The capsule drug device: Novel approach for drug delivery to the eye","volume":"50","author":"Molokhia","year":"2010","journal-title":"Vision Res."},{"key":"10.1016\/j.biopha.2018.08.138_bib0135","doi-asserted-by":"crossref","first-page":"5403","DOI":"10.1167\/iovs.10-5392","article-title":"Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications","volume":"51","author":"Edelhauser","year":"2010","journal-title":"Investig. Opthalmol. Vis. Sci."},{"key":"10.1016\/j.biopha.2018.08.138_bib0140","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1159\/000431128","article-title":"Retinal anatomy and pathology","volume":"55","author":"Gupta","year":"2015","journal-title":"Dev. Ophthalmol."},{"key":"10.1016\/j.biopha.2018.08.138_bib0145","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s11095-008-9745-6","article-title":"Investigating the movement of intravitreal human serum albumin nanoparticles in the vitreous and retina","volume":"26","author":"Kim","year":"2009","journal-title":"Pharm. Res."},{"key":"10.1016\/j.biopha.2018.08.138_bib0150","first-page":"1","article-title":"Ocular drug distribution after topical administration: population pharmacokinetic model in rabbits","author":"Djebli","year":"2016","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.biopha.2018.08.138_bib0155","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s13346-016-0339-2","article-title":"A comprehensive insight on ocular pharmacokinetics","volume":"6","author":"Agrahari","year":"2016","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.biopha.2018.08.138_bib0160","series-title":"Handb. Exp. Pharmacol.","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/164_2016_32","article-title":"Ocular pharmacokinetics","author":"Durairaj","year":"2016"},{"key":"10.1016\/j.biopha.2018.08.138_bib0165","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1089\/jop.2015.0133","article-title":"Posterior segment drug delivery devices: current and novel therapies in development","volume":"32","author":"Bansal","year":"2016","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2018.08.138_bib0170","doi-asserted-by":"crossref","first-page":"137","DOI":"10.4155\/tde-2017-0088","article-title":"Recent advances in topical nano drug-delivery systems for the anterior ocular segment","volume":"9","author":"Lakhani","year":"2018","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.biopha.2018.08.138_bib0175","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2174\/156720112801323125","article-title":"Controlled and continuous release ocular drug delivery systems: pros and cons","volume":"9","author":"Abdelkader","year":"2012","journal-title":"Curr. Drug Deliv."},{"key":"10.1016\/j.biopha.2018.08.138_bib0180","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1089\/jop.2012.0040","article-title":"Evaluation of the intravenous and topical routes for ocular delivery of Hesperidin and hesperetin","volume":"28","author":"Srirangam","year":"2012","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2018.08.138_bib0185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1517\/17425247.2014.935338","article-title":"Advances in ocular drug delivery: emphasis on the posterior segment","volume":"11","author":"Kang-Mieler","year":"2014","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.biopha.2018.08.138_bib0190","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jconrel.2010.08.028","article-title":"Barrier analysis of periocular drug delivery to the posterior segment","volume":"148","author":"Ranta","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.biopha.2018.08.138_bib0195","series-title":"Biodrug Delivery Systems Fundamentals, Applications and Clinical Development","author":"Swarbrick","year":"2010"},{"key":"10.1016\/j.biopha.2018.08.138_bib0200","first-page":"1198","article-title":"Suprachoroidal delivery in a rabbit ex vivo eye model: influence of drug properties, regional differences in delivery, and comparison with intravitreal and intracameral routes","volume":"19","author":"Kadam","year":"2013","journal-title":"Mol. Vis."},{"key":"10.1016\/j.biopha.2018.08.138_bib0205","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.ymthe.2017.03.023","article-title":"FDA-approved oligonucleotide therapies in 2017","volume":"25","author":"Stein","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biopha.2018.08.138_bib0210","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1007\/s00417-017-3647-4","article-title":"Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti\u2013vascular endothelial growth factor therapy of macular diseases, Graefe\u2019s Arch","volume":"255","author":"Lanzetta","year":"2017","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.biopha.2018.08.138_bib0215","first-page":"1","article-title":"Local and systemic complications after intravitreal administration of anti-vascular endothelial growth factor agents in the treatment of different ocular diseases: a five-year retrospective study","author":"Nuzzi","year":"2013","journal-title":"Semin. Ophthalmol."},{"key":"10.1016\/j.biopha.2018.08.138_bib0220","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/eye.2013.107","article-title":"Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature","volume":"27","author":"Falavarjani","year":"2013","journal-title":"Eye"},{"key":"10.1016\/j.biopha.2018.08.138_bib0225","first-page":"1","article-title":"Current nanotechnology approaches for the treatment and management of diabetic retinopathy","author":"Fangueiro","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.biopha.2018.08.138_bib0230","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1258\/0956462981922098","article-title":"Intravitreal sustained-release ganciclovir implantation to control cytomegalovirus retinitis in AIDS","volume":"9","author":"Dhillon","year":"1998","journal-title":"Int. J. STD AIDS"},{"key":"10.1016\/j.biopha.2018.08.138_bib0235","first-page":"1","article-title":"Intravitreal devices for the treatment of vitreous inflammation","volume":"2012","author":"Christoforidis","year":"2012","journal-title":"Mediators Inflamm."},{"key":"10.1016\/j.biopha.2018.08.138_bib0240","series-title":"Biomaterials and Regenerative Medicine in Ophthalmology","author":"Chirila","year":"2016"},{"key":"10.1016\/j.biopha.2018.08.138_bib0245","first-page":"317","article-title":"Sustained release intraocular drug delivery devices for treatment of uveitis","volume":"6","author":"Haghjou","year":"2011","journal-title":"J. Ophthalmic Vis. Res."},{"key":"10.1016\/j.biopha.2018.08.138_bib0250","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.ophtha.2006.02.021","article-title":"Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis. Thirty-four-week results of a multicenter randomized clinical study","volume":"113","author":"Jaffe","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1016\/j.biopha.2018.08.138_bib0255","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3109\/09273948.2014.986583","article-title":"Outcome of multiple implants and dissociation of fluocinolone acetonide intravitreal implant (Retisert) in a series of 187 consecutive implants","volume":"23","author":"Freitas-Neto","year":"2015","journal-title":"Ocul. Immunol. Inflamm."},{"key":"10.1016\/j.biopha.2018.08.138_bib0260","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1517\/17425247.5.9.1039","article-title":"Iluvien: a new sustained delivery technology for posterior eye disease","volume":"5","author":"Kane","year":"2008","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.biopha.2018.08.138_bib0265","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2147\/OPTH.S79785","article-title":"A novel intravitreal fluocinolone acetonide implant (Iluvien\u00ae) in the treatment of patients with chronic diabetic macular edema that is insufficiently responsive to other medical treatment options: a case series","volume":"9","author":"Schmit-Eilenberger","year":"2015","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.biopha.2018.08.138_bib0270","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1517\/13543784.2016.1128893","article-title":"Moving forward in uveitis therapy: preclinical to phase II clinical trial drug development","volume":"25","author":"Salazar-M\u00e9ndez","year":"2016","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.biopha.2018.08.138_bib0275","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1080\/17425247.2016.1188800","article-title":"Drug, delivery and devices for diabetic retinopathy (3Ds in DR)","volume":"13","author":"Nirmal","year":"2016","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.biopha.2018.08.138_bib0280","first-page":"679","article-title":"Intravitreal bioerudivel sustained-release triamcinolone microspheres system (RETAAC). Preliminary report of its potential usefulnes for the treatment of diabetic macular edema","volume":"81","author":"a Cardillo","year":"2006","journal-title":"Arch. Soc. Esp. Oftalmol."},{"key":"10.1016\/j.biopha.2018.08.138_bib0285","series-title":"A New Vision for the Eye: Unmet Ocular Drug Delivery Needs","author":"Rivers","year":"2015"},{"key":"10.1016\/j.biopha.2018.08.138_bib0290","first-page":"1","article-title":"Ocular translational science: a review of development steps and paths","author":"Mann","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.biopha.2018.08.138_bib0295","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1089\/jop.2006.22.121","article-title":"Therapeutic and toxicological evaluations of cyclosporine a microspheres as a treatment vehicle for uveitis in rabbits","volume":"22","author":"He","year":"2006","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2018.08.138_bib0300","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/j.1463-5224.2010.00807.x","article-title":"Long-term outcome after implantation of a suprachoroidal cyclosporine drug delivery device in horses with recurrent uveitis","volume":"13","author":"Gilger","year":"2010","journal-title":"Vet. Ophthalmol."},{"key":"10.1016\/j.biopha.2018.08.138_bib0305","first-page":"54","article-title":"Ocular drug delivery systems for the posterior segment : a review","author":"Kuno","year":"2012","journal-title":"Retin. Today"},{"key":"10.1016\/j.biopha.2018.08.138_bib0310","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1016\/S0161-6420(01)00839-9","article-title":"Randomized clinical trial of surodex steroid drug delivery system for cataract surgery anterior versus posterior placement of two surodex in the eye","volume":"108","author":"Tan","year":"2001","journal-title":"Ophthalmology"},{"key":"10.1016\/j.biopha.2018.08.138_bib0315","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.ajo.2004.10.052","article-title":"Use of surodex in phacotrabeculectomy surgery","volume":"139","author":"Seah","year":"2005","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.biopha.2018.08.138_bib0320","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1159\/000342160","article-title":"Repeated intravitreal dexamethasone implant (Ozurdex\u00ae) for retinal vein occlusion","volume":"229","author":"Querques","year":"2013","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.biopha.2018.08.138_bib0325","first-page":"1043","article-title":"Critical appraisal of the clinical utility of the dexamethasone intravitreal implant (Ozurdex\u00ae) for the treatment of macular edema related to branch retinal vein occlusion or central retinal vein occlusion","volume":"5","author":"Chan","year":"2011","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.biopha.2018.08.138_bib0330","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.2147\/OPTH.S48364","article-title":"Preliminary results of an intravitreal dexamethasone implant (Ozurdex(R)) in patients with persistent diabetic macular edema","volume":"7","author":"Pacella","year":"2013","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.biopha.2018.08.138_bib0335","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.ophtha.2010.03.032","article-title":"Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion","volume":"117","author":"Haller","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.biopha.2018.08.138_bib0340","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/aos.12020","article-title":"Functional and anatomical results after a single intravitreal Ozurdex injection in retinal vein occlusion: a 6-month follow-up - The SOLO study","volume":"91","author":"Bezatis","year":"2013","journal-title":"Acta Ophthalmol."},{"key":"10.1016\/j.biopha.2018.08.138_bib0345","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2165\/11530970-000000000-00000","article-title":"Biodegradable intraocular therapies for retinal disorders: progress to date","volume":"27","author":"Kuno","year":"2010","journal-title":"Drugs Aging"},{"key":"10.1016\/j.biopha.2018.08.138_bib0350","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ajo.2016.07.013","article-title":"Long-term follow-up of patients with retinitis pigmentosa receiving intraocular ciliary neurotrophic factor implants","volume":"170","author":"Birch","year":"2016","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.biopha.2018.08.138_bib0355","doi-asserted-by":"crossref","first-page":"597","DOI":"10.3109\/1061186X.2015.1052073","article-title":"Recent developments in ocular drug delivery","volume":"23","author":"Chen","year":"2015","journal-title":"J. Drug Target"},{"key":"10.1016\/j.biopha.2018.08.138_bib0360","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1167\/tvst.3.4.1","article-title":"One-year feasibility study of replenish MicroPump for intravitreal drug delivery: a pilot study","volume":"3","author":"Gutierrez-Hernandez","year":"2014","journal-title":"Transl. Vis. Sci. Technol."},{"key":"10.1016\/j.biopha.2018.08.138_bib0365","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3109\/02713680903521936","article-title":"Mini drug pump for ophthalmic use","volume":"35","author":"Saati","year":"2010","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.biopha.2018.08.138_bib0370","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.1167\/iovs.12-9872","article-title":"Targeted administration into the suprachoroidal space using a microneedle for drug delivery to the posterior segment of the eye","volume":"53","author":"Patel","year":"2012","journal-title":"Investig. Opthalmol. Vis. Sci."},{"key":"10.1016\/j.biopha.2018.08.138_bib0375","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.exer.2016.10.011","article-title":"Distribution of particles, small molecules and polymeric formulation excipients in the suprachoroidal space after microneedle injection","volume":"153","author":"Chiang","year":"2016","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.biopha.2018.08.138_bib0380","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s11095-010-0271-y","article-title":"Suprachoroidal drug delivery to the back of the eye using hollow microneedles","volume":"28","author":"Patel","year":"2011","journal-title":"Pharm. Res."},{"key":"10.1016\/j.biopha.2018.08.138_bib0385","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/jop.2017.0121","article-title":"Intravitreal, subretinal, and suprachoroidal injections: evolution of microneedles for drug delivery","volume":"34","author":"Hartman","year":"2018","journal-title":"J. Ocul. Pharmacol."},{"key":"10.1016\/j.biopha.2018.08.138_bib0390","doi-asserted-by":"crossref","first-page":"173","DOI":"10.4103\/0975-7406.116792","article-title":"Updates on drug bioavailability and delivery to posterior segment of eye","volume":"5","author":"Gupta","year":"2013","journal-title":"J. Pharm. Bioallied Sci."},{"key":"10.1016\/j.biopha.2018.08.138_bib0395","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.drudis.2010.12.004","article-title":"Drug delivery to the posterior segment of the eye","volume":"16","author":"Thrimawithana","year":"2011","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.biopha.2018.08.138_bib0400","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1167\/iovs.13-13707","article-title":"Drug and gene delivery to the back of the eye: from bench to bedside","volume":"55","author":"Rowe-Rendleman","year":"2014","journal-title":"Investig. Opthalmol. Vis. Sci."},{"key":"10.1016\/j.biopha.2018.08.138_bib0405","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1016\/j.addr.2005.09.007","article-title":"Ocular delivery using poly(ortho esters)","volume":"57","author":"Heller","year":"2005","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.biopha.2018.08.138_bib0410","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12886-016-0188-2","article-title":"Drug discovery in ophthalmology: past success, present challenges, and future opportunities","volume":"16","author":"Gower","year":"2016","journal-title":"BMC Ophthalmol."},{"key":"10.1016\/j.biopha.2018.08.138_bib0415","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12348-014-0022-z","article-title":"Pharmacokinetics of intravitreal antibiotics in endophthalmitis","volume":"4","author":"Radhika","year":"2014","journal-title":"J. Ophthalmic Inflamm. Infect."},{"key":"10.1016\/j.biopha.2018.08.138_bib0420","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1080\/17425247.2017.1266334","article-title":"Basic principles and current status of transcorneal and transscleral iontophoresis","volume":"14","author":"Gratieri","year":"2017","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.biopha.2018.08.138_bib0425","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1007\/s11095-009-0042-9","article-title":"New techniques for drug delivery to the posterior eye segment","volume":"27","author":"Eljarrat-Binstock","year":"2010","journal-title":"Pharm. Res."},{"key":"10.1016\/j.biopha.2018.08.138_bib0430","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1167\/tvst.4.3.11","article-title":"Topical ocular drug delivery to the back of the eye by mucus-penetrating particles","volume":"4","author":"Schopf","year":"2015","journal-title":"Transl. Vis. Sci. Technol."},{"key":"10.1016\/j.biopha.2018.08.138_bib0435","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1016\/j.nano.2016.04.006","article-title":"Mucus-penetrating nanoparticles made with \u201cmucoadhesive\u201d poly(vinyl alcohol)","volume":"12","author":"Popov","year":"2016","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"10.1016\/j.biopha.2018.08.138_bib0440","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1167\/iovs.11-9064","article-title":"Antiangiogenic activity of aganirsen in nonhuman primate and rodent models of retinal neovascular disease after topical administration","volume":"53","author":"Cloutier","year":"2012","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.biopha.2018.08.138_bib0445","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.ajo.2006.05.045","article-title":"Cannulation of the suprachoroidal space: a novel drug delivery methodology to the posterior segment","volume":"142","author":"Olsen","year":"2006","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.biopha.2018.08.138_bib0450","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1039\/c1lc20134d","article-title":"On-demand controlled release of docetaxel from a battery-less MEMS drug delivery device","volume":"11","author":"Pirmoradi","year":"2011","journal-title":"Lab Chip"},{"key":"10.1016\/j.biopha.2018.08.138_bib0455","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.preteyeres.2013.04.001","article-title":"Nanomedicines for back of the eye drug delivery, gene delivery, and imaging","volume":"36","author":"Kompella","year":"2013","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.biopha.2018.08.138_bib0460","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.sjopt.2014.02.009","article-title":"Nanocarriers of nanotechnology in retinal diseases","volume":"28","author":"Al-Halafi","year":"2014","journal-title":"Saudi J. Ophthalmol."},{"key":"10.1016\/j.biopha.2018.08.138_bib0465","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3390\/jfb6020379","article-title":"Lipid nanoparticles for ocular gene delivery","volume":"6","author":"Wang","year":"2015","journal-title":"J. Funct. Biomater."},{"key":"10.1016\/j.biopha.2018.08.138_bib0470","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.colsurfb.2011.06.025","article-title":"Nanostructured lipid carriers for triamcinolone acetonide delivery to the posterior segment of the eye","volume":"88","author":"Araujo","year":"2011","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.biopha.2018.08.138_bib0475","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.ijpharm.2012.07.024","article-title":"Liposomal diclofenac eye drop formulations targeting the retina: formulation stability improvement using surface modification of liposomes","volume":"436","author":"Fujisawa","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.biopha.2018.08.138_bib0480","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jconrel.2015.01.001","article-title":"Light-responsive nanoparticle depot to control release of a small molecule angiogenesis inhibitor in the posterior segment of the eye","volume":"200","author":"Huu","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.biopha.2018.08.138_bib0485","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ijpharm.2013.06.024","article-title":"Drug delivery to the ocular posterior segment using lipid emulsion via eye drop administration: effect of emulsion formulations and surface modification","volume":"453","author":"Ying","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.biopha.2018.08.138_bib0490","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.apsb.2016.09.001","article-title":"Nanotechnology-based strategies for treatment of ocular disease","volume":"7","author":"Weng","year":"2017","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.biopha.2018.08.138_bib0495","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/molecules23020295","article-title":"Cell penetrating peptides as molecular carriers for anti-cancer agents","volume":"23","author":"Borrelli","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.biopha.2018.08.138_bib0500","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms17020185","article-title":"Applications and challenges for use of cell-penetrating peptides as delivery vectors for peptide and protein cargos","volume":"17","author":"Kristensen","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2018.08.138_bib0505","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jconrel.2016.02.002","article-title":"Emerging landscape of cell penetrating peptide in reprogramming and gene editing","volume":"226","author":"Liu","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.biopha.2018.08.138_bib0510","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.2174\/0929867322666150114163308","article-title":"A promising future for peptides in ophthalmology: work effectively and smartly","volume":"22","author":"Sun","year":"2015","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.biopha.2018.08.138_bib0515","first-page":"609","article-title":"Conjugation of cell-penetrating peptides with poly(lactic-co-glycolic acid)-polyethylene glycol nanoparticles improves ocular drug delivery","volume":"10","author":"Vasconcelos","year":"2015","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.biopha.2018.08.138_bib0520","first-page":"1029","article-title":"Novel epithelial cell adhesion molecule antibody conjugated polyethyleneimine-capped gold nanoparticles for enhanced and targeted small interfering RNA delivery to retinoblastoma cells","volume":"19","author":"Mitra","year":"2013","journal-title":"Mol. Vis."},{"key":"10.1016\/j.biopha.2018.08.138_bib0525","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jconrel.2009.02.020","article-title":"Design and evaluation of a liposomal delivery system targeting the posterior segment of the eye","volume":"136","author":"Hironaka","year":"2009","journal-title":"J. Control. Release"},{"key":"10.1016\/j.biopha.2018.08.138_bib0530","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1002\/smll.201303433","article-title":"Topical delivery of avastin to the posterior segment of the eye in vivo using annexin A5-associated liposomes","volume":"10","author":"Davis","year":"2014","journal-title":"Small"},{"key":"10.1016\/j.biopha.2018.08.138_bib0535","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1211\/jpp.57.12.0005","article-title":"Size-dependent disposition of nanoparticles and microparticles following subconjunctival administration","volume":"57","author":"Amrite","year":"2005","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.biopha.2018.08.138_bib0540","doi-asserted-by":"crossref","first-page":"768","DOI":"10.4103\/0301-4738.138301","article-title":"Nanostructure-based platforms-current prospective in ophthalmic drug delivery","volume":"62","author":"Sharma","year":"2014","journal-title":"Indian J. Ophthalmol."},{"key":"10.1016\/j.biopha.2018.08.138_bib0545","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jconrel.2014.05.031","article-title":"Nanotherapy for posterior eye diseases","volume":"193","author":"Kaur","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.biopha.2018.08.138_bib0550","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1159\/000345477","article-title":"Think global - act local: intravitreal drug delivery systems in chronic noninfectious uveitis","volume":"49","author":"Hazirolan","year":"2013","journal-title":"Ophthalmic Res."},{"key":"10.1016\/j.biopha.2018.08.138_bib0555","series-title":"Adv. Ocul. Drug Deliv., Research Signpost\/Transworld Research Network, Trivandrum","first-page":"33","article-title":"Transscleral drug delivery to the posterior segment of the eye : particulate and colloidal formulations and biopharmaceutical considerations","author":"Srirangam","year":"2012"},{"key":"10.1016\/j.biopha.2018.08.138_bib0560","doi-asserted-by":"crossref","first-page":"4749","DOI":"10.1167\/iovs.10-6291","article-title":"Pharmacokinetics of pars plana intravitreal injections versus microcannula suprachoroidal injections of Bevacizumab in a porcine model","volume":"52","author":"Olsen","year":"2011","journal-title":"Investig. Opthalmol. Vis. Sci."},{"key":"10.1016\/j.biopha.2018.08.138_bib0565","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.ophtha.2009.11.027","article-title":"Evaluation of an intravitreal fluocinolone acetonide implant versus standard systemic therapy in noninfectious posterior uveitis","volume":"117","author":"Pavesio","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.biopha.2018.08.138_bib0570","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ijpharm.2016.09.013","article-title":"Intravitreal injection of rapamycin-loaded polymeric micelles for inhibition of ocular inflammation in rat model","volume":"513","author":"Wu","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.biopha.2018.08.138_bib0575","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1208\/s12249-014-0244-2","article-title":"Nanomicellar topical aqueous drop formulation of rapamycin for back-of-the-eye delivery","volume":"16","author":"Cholkar","year":"2014","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.biopha.2018.08.138_bib0580","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1167\/tvst.4.3.1","article-title":"Topical, aqueous, clear cyclosporine formulation design for anterior and posterior ocular delivery","volume":"4","author":"Cholkar","year":"2018","journal-title":"Transl. Vis. Sci. Technol."},{"key":"10.1016\/j.biopha.2018.08.138_bib0585","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.colsurfb.2015.12.053","article-title":"Micellar delivery of dasatinib for the inhibition of pathologic cellular processes of the retinal pigment epithelium","volume":"140","author":"Li","year":"2016","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.biopha.2018.08.138_bib0590","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1089\/jop.2014.0152","article-title":"Development and evaluation of dexamethasone nanomicelles with potential for treating posterior uveitis after topical application","volume":"31","author":"Patel","year":"2015","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2018.08.138_bib0595","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1002\/adhm.201300696","article-title":"Particle-stabilized emulsion droplets for gravity-mediated targeting in the posterior segment of the eye","volume":"3","author":"Kim","year":"2014","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.biopha.2018.08.138_bib0600","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ejpb.2016.10.015","article-title":"Topical ophthalmic lipid nanoparticle formulations (SLN, NLC) of indomethacin for delivery to the posterior segment ocular tissues","volume":"109","author":"Balguri","year":"2016","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.biopha.2018.08.138_bib0605","first-page":"394","article-title":"Feasibility of drug delivery to the eye\u2019s posterior segment by topical instillation of PLGA nanoparticles","volume":"12","author":"Tahara","year":"2017","journal-title":"Asian J. Pharm. Sci."},{"key":"10.1016\/j.biopha.2018.08.138_bib0610","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1002\/jbm.a.35446","article-title":"Albuminated PLGA nanoparticles containing bevacizumab intended for ocular neovascularization treatment","volume":"103","author":"Varshochian","year":"2015","journal-title":"J. Biomed. Mater. Res."},{"key":"10.1016\/j.biopha.2018.08.138_bib0615","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ejpb.2014.04.011","article-title":"A novel technology using transscleral ultrasound to deliver protein loaded nanoparticles","volume":"88","author":"Huang","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.biopha.2018.08.138_bib0620","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ejpb.2011.01.019","article-title":"European Journal of Pharmaceutics and Biopharmaceutics Edaravone-loaded liposomes for retinal protection against oxidative stress-induced retinal damage","volume":"79","author":"Hironaka","year":"2011","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.biopha.2018.08.138_bib0625","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.ejpb.2012.10.014","article-title":"Retinal drug delivery using eyedrop preparations of poly- L -lysine-modified liposomes","volume":"83","author":"Sasaki","year":"2013","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.biopha.2018.08.138_bib0630","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1248\/yakushi.12-00234-3","article-title":"Non-invasive ophthalmic liposomes for nucleic acid delivery to posterior segment of eye","volume":"132","author":"Takashima","year":"2012","journal-title":"Yakugaku Zasshi"},{"key":"10.1016\/j.biopha.2018.08.138_bib0635","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jconrel.2015.01.001","article-title":"Light-responsive nanoparticle depot to control release of a small molecule angiogenesis inhibitor in the posterior segment of the eye","volume":"200","author":"Huu","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.biopha.2018.08.138_bib0640","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.ijpharm.2013.10.033","article-title":"In vitro and in vivo studies on ocular vitamin A palmitate cationic liposomal in situ gels","volume":"458","author":"He","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.biopha.2018.08.138_bib0645","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3109\/02713683.2013.819927","article-title":"Tacrolimus-loaded PLGA implants: in vivo release and ocular toxicity","volume":"39","author":"Souza","year":"2014","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.biopha.2018.08.138_bib0650","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1167\/iovs.13-13599","article-title":"Systemic treatment with glutathione PEGylated liposomal methylprednisolone (2B3-201) improves therapeutic efficacy in a model of ocular inflammation","volume":"55","author":"Reijerkerk","year":"2014","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.biopha.2018.08.138_bib0655","doi-asserted-by":"crossref","first-page":"5978","DOI":"10.1016\/j.biomaterials.2013.04.035","article-title":"Hyaluronan-modified core-shell liponanoparticles targeting CD44-positive retinal pigment epithelium cells via intravitreal injection","volume":"34","author":"Gan","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.biopha.2018.08.138_bib0660","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ejpb.2015.02.006","article-title":"Evaluation of topical hesperetin matrix film for back-of-the-eye delivery","volume":"92","author":"Adelli","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.biopha.2018.08.138_bib0665","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/09205063.2012.745714","article-title":"Evaluation of RGD peptide hydrogel in the posterior segment of the rabbit eye","volume":"24","author":"Wang","year":"2013","journal-title":"J. Biomater. Sci. Polym. Ed."},{"key":"10.1016\/j.biopha.2018.08.138_bib0670","doi-asserted-by":"crossref","first-page":"14488","DOI":"10.1039\/C4NR04761C","article-title":"Supramolecular nanofibers of triamcinolone acetonide for uveitis therapy","volume":"6","author":"Li","year":"2014","journal-title":"Nanoscale"},{"key":"10.1016\/j.biopha.2018.08.138_bib0675","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ijpharm.2015.05.071","article-title":"An injectable thermosensitive polymeric hydrogel for sustained release of Avastin 1 to treat posterior segment disease","volume":"490","author":"Xie","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.biopha.2018.08.138_bib0680","doi-asserted-by":"crossref","DOI":"10.1208\/s12249-014-0100-4","article-title":"Novel dexamethasone-loaded nanomicelles for the intermediate and posterior segment uveitis","author":"Vaishya","year":"2014","journal-title":"AAPS PharmSci"},{"key":"10.1016\/j.biopha.2018.08.138_bib0685","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ejpb.2014.12.029","article-title":"Silk hydrogels for sustained ocular delivery of anti-vascular endothelial growth factor (anti-VEGF) therapeutics","volume":"95","author":"Lovett","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.biopha.2018.08.138_bib0690","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1007\/s10439-015-1314-7","article-title":"Controlled and extended release of a model protein from a microsphere-hydrogel drug delivery system","volume":"43","author":"Engineering","year":"2015","journal-title":"Ann. Biomed. Eng."},{"key":"10.1016\/j.biopha.2018.08.138_bib0695","doi-asserted-by":"crossref","first-page":"653","DOI":"10.3109\/02713683.2015.1050738","article-title":"Hydrogel ring for topical drug delivery to the ocular posterior segment hydrogel ring for topical drug delivery to the ocular posterior segment","volume":"41","author":"Taylor","year":"2016","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.biopha.2018.08.138_bib0700","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.actbio.2013.11.004","article-title":"A polymeric device for controlled transscleral multi-drug delivery to the posterior segment of the eye","volume":"10","author":"Nagai","year":"2014","journal-title":"Acta Biomater."}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332218306863?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332218306863?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T02:41:20Z","timestamp":1766025680000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332218306863"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":140,"alternative-id":["S0753332218306863"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2018.08.138","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A review on recent drug delivery systems for posterior segment of eye","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2018.08.138","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}